Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".
作者信息
Kudo Masatoshi, Tsuchiya Kaoru, Yamashita Tatsuya, Koga Hironori, Nakagawa Yuki, Ikeda Masafumi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
出版信息
Liver Cancer. 2024 May 6;13(6):671-673. doi: 10.1159/000539205. eCollection 2024 Dec.
Abstract
摘要
相似文献
1
Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".关于“在接受阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者中，因贝伐珠单抗的特殊不良事件而跳过贝伐珠单抗的影响：III期IMbrave150研究的探索性分析”的信件回复
Liver Cancer. 2024 May 6;13(6):671-673. doi: 10.1159/000539205. eCollection 2024 Dec.
2
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.在接受阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者中，因贝伐珠单抗特殊关注不良事件而跳过贝伐珠单抗的影响：III期IMbrave150研究的探索性分析
Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. eCollection 2024 Aug.
3
Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".关于“在接受阿替利珠单抗联合贝伐单抗治疗的不可切除肝细胞癌患者中，因贝伐单抗的特殊不良事件而跳过贝伐单抗的影响：III期IMbrave150研究的探索性分析”的信函
Liver Cancer. 2024 Mar 27;13(6):669-670. doi: 10.1159/000538580. eCollection 2024 Dec.
4
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
5
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.不可切除肝细胞癌患者的缓解深度和持续时间与生存相关：IMbrave150探索性分析
Liver Cancer. 2025 Mar 3:1-16. doi: 10.1159/000544981.
6
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.阿替利珠单抗联合贝伐单抗用于不符合IMbrave150纳入标准的不可切除肝细胞癌患者的早期反应及安全性
Hepatol Res. 2021 Sep;51(9):979-989. doi: 10.1111/hepr.13693. Epub 2021 Jul 20.
7
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗中国不可切除肝细胞癌亚组患者：3期随机、开放标签IMbrave150研究
Liver Cancer. 2021 Jul;10(4):296-308. doi: 10.1159/000513486. Epub 2021 Apr 23.
8
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
9
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.IMbrave150：阿替利珠单抗联合贝伐单抗与索拉非尼治疗巴塞罗那临床肝癌分期B期不可切除肝细胞癌患者的疗效和安全性：一项III期研究的探索性分析
Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. eCollection 2023 Aug.
10
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
本文引用的文献
1
Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".关于“在接受阿替利珠单抗联合贝伐单抗治疗的不可切除肝细胞癌患者中，因贝伐单抗的特殊不良事件而跳过贝伐单抗的影响：III期IMbrave150研究的探索性分析”的信函
Liver Cancer. 2024 Mar 27;13(6):669-670. doi: 10.1159/000538580. eCollection 2024 Dec.
2
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.在接受阿替利珠单抗联合贝伐珠单抗治疗的不可切除肝细胞癌患者中，因贝伐珠单抗特殊关注不良事件而跳过贝伐珠单抗的影响：III期IMbrave150研究的探索性分析
Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. eCollection 2024 Aug.
3
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.预测阿特珠单抗和贝伐珠单抗治疗肝细胞癌患者的结局。
Int J Mol Sci. 2023 Jul 22;24(14):11799. doi: 10.3390/ijms241411799.
4
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.贝伐单抗早期中断与阿替利珠单抗联合贝伐单抗治疗晚期肝细胞癌疗效的关联：一项里程碑分析。
Hepatol Res. 2022 May;52(5):462-470. doi: 10.1111/hepr.13748. Epub 2022 Feb 9.
Zotero 插件